• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

A Giant Stumbles

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-07-01-2001
Volume 0
Issue 0

Basel, Switzerland—Roche, which recently slashed its work force by 3,000, maintains that it will remain independent even after the sale of 20 percent of the company to Novartis. Franz Humer, the troubled company’s chairman, says the founding family supports Roche’s strategy.

Articles in this issue
Amgen's New Dream Team
Pharmacies: OTC Price Wars
One Disease at a Time
Overview of the Industry: A World of Opportunities
The Power Shift
Access: Novartis Gives It Away
A Giant Stumbles
CRO's Cross Over NOW
Overruled: No More Dual Pricing
Submerged
Generic Threat
Bottom Line Booster
Recent Videos
Paul Howe
Paul Howe
Ash Shehata
Related Content
FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without Aura

FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without Aura

Don Tracy, Associate Editor
January 31st 2025
Article

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 hours, and reduces the need for rescue medication.

The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations

The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations

Miranda Schmalfuhs
January 30th 2025
Podcast

Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.

Paul Ollinger is a writer, stand-up comedian, and host of the Reasonably Happy podcast

Why Frontline Sales Have and Will Continue to be a Foundation for Long-term Career Success

Michael Wong
January 31st 2025
Article

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data

What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data

LabVantage Solutions
December 11th 2024
Podcast

When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.

Stock.adobe.com

Senior Senators Introduce Bill to Force DTC Drug Advertisements to Include List Price

Mike Hollan
January 31st 2025
Article

Senators Durbin and Grassley proposed the new regulations for direct-to-consumer pharma advertising.

Pharma Pulse 1/31/25: What Round II of Medicare Part D Drug Prices Signify, 2025 Digital Healthcare Outlook & more

Pharma Pulse 1/31/25: What Round II of Medicare Part D Drug Prices Signify, 2025 Digital Healthcare Outlook & more

Miranda Schmalfuhs
January 31st 2025
Article

The latest news for pharma industry insiders.